Standard Cosentyx Dosing Schedule
Cosentyx (secukinumab) starts with loading doses, then shifts to maintenance. For plaque psoriasis in adults, it's 300 mg (two 150 mg subcutaneous injections) at weeks 0, 1, 2, 3, 4, then every 4 weeks. For psoriatic arthritis or ankylosing spondylitis, it's 150 mg (one injection) at the same initial weeks, then every 4 weeks—doubled to 300 mg if needed for psoriasis. Doses stay fixed; no routine increases beyond loading.[1][2]
When Might Doctors Increase the Dose?
Dose escalation happens only for inadequate response. Guidelines allow bumping from 150 mg to 300 mg every 4 weeks in psoriatic arthritis or axial spondyloarthritis if symptoms persist after 12-16 weeks on lower dose. This isn't frequent—typically one-time adjustment, not repeated. Rheumatology experts monitor via clinical scores like ASDAS or PASI.[1][3]
How Often Do Patients Need Dose Increases?
Real-world data shows increases in under 20% of cases, often after 3-6 months of suboptimal control. Studies report sustained efficacy on standard dosing for most; escalations reverse in 30-50% upon re-lowering. Frequency depends on condition—rarer in psoriasis than arthritis.[3][4]
What If Response Is Still Poor After Increase?
Switch therapies rather than further escalate Cosentyx, per ACR guidelines. Options include TNF inhibitors, IL-17 peers like Taltz, or IL-23s like Tremfya. No data supports Cosentyx beyond 300 mg.[1][5]
Risks of Dose Increases
Higher doses raise infection risk slightly (e.g., upper respiratory, 10-15% incidence). Monitor for IBD flares or candidiasis. Cost jumps ~2x; insurance often requires failure documentation first.[2][6]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: Nash P, et al. "Secukinumab Dose Escalation in PsA." Rheumatology (Oxford). 2021.
[4]: DrugPatentWatch.com - Cosentyx Patents & Pricing
[5]: ACR Guidelines for Psoriatic Arthritis. 2021.
[6]: Mease PJ, et al. "Safety of Secukinumab." Lancet. 2017.